Results 171 to 180 of about 65,496 (283)

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1984-1996, March 2026.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou, Huilin Tang, Bingyu Zhang, Dazheng Zhang, Yiwen Lu, Lu Li, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Health economic evaluation of dipeptidyl peptidase-4 inhibitors

Indian Journal of Endocrinology and Metabolism, 2011
Vishvas Garg
doaj   +1 more source

Increased dipeptidyl peptidase 4 in patients with concomitant transthyretin cardiac amyloidosis and severe aortic stenosis. [PDF]

Int J Cardiol Heart Vasc
Holt MF, Michelsen AE, Flø A, Russell K, Beitnes JO, Kløve SF, Hodt A, Gullestad L, Aukrust P, Gude E, Broch K, Ueland T.   +11 more
europepmc   +1 more source

Literature‐informed ensemble machine learning for three‐year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1997-2026, March 2026.
Abstract Introduction Diabetic kidney disease (DKD) and diabetic nephropathy (DN) affect around 40% of diabetic patients but lack accurate risk prediction tools that include social determinants and demographic complexity. We developed and validated an ensemble machine learning model for three‐year DKD/DN risk prediction with deployment readiness ...
Ayla M. Tourkmani, Turki J. Al‐Harbi, Ahmad Abdullah Alghamdi, Ibrahim M. Youzghadli, Faris Saad Alosaimi, Ahmed Y. Azzam   +5 more
wiley   +1 more source

Efficacy and safety of bi-weekly cofrogliptin treatment replacing daily dipeptidyl peptidase-4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open-label, randomized controlled phase 2 trial. [PDF]

Diabetes Obes Metab
Abstract Aim This study aimed to investigate the efficacy and safety of bi‐weekly cofrogliptin treatment as a replacement for daily dipeptidyl peptidase‐4 inhibitors (DPP‐4is) in Chinese patients with type 2 diabetes mellitus (T2DM). Methods This multicenter, open‐label, randomized controlled study assigned participants in a 1:1 ratio to either the ...
Pan C, Jiang H, Feng Y, Wang S, Zhang J, Wang Z, Zhou Y, Li F, Zhang Z, Li Y, Chen L.   +10 more
europepmc   +2 more sources

Dipeptidyl Peptidase-4 Activity Measurement [PDF]

, 2020
openaire   +1 more source

Exertional heat stress and intestinal barrier injury: Does chronic disease add fuel to the fire?

Experimental Physiology, EarlyView.
Oliver R. Gibson, Zachary J. McKenna
wiley   +1 more source

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2027-2037, March 2026.
Abstract Aim This study evaluated the efficacy and safety of empagliflozin 10 and 25 mg compared to placebo as add‐on treatment for people with type 2 diabetes mellitus (T2DM) uncontrolled after ≥8 weeks of treatment with metformin and sitagliptin. Materials and Methods A randomised, double‐blind, multicentre, therapeutic confirmatory, phase 3 clinical
Seung‐Hwan Lee, Kyung Ah Han, Eun‐Gyoung Hong, Jun Goo Kang, Choon Hee Chung, Jong Chul Won, Eon Ju Jeon, Jung‐Hwan Cho, Ho Chan Cho, Sin Gon Kim, Eun Seok Kang, So Hun Kim, Hae Jin Kim, In‐Kyung Jeong, Sung Wan Chun, Young Min Cho   +15 more
wiley   +1 more source

In Vivo Inhibition of Dipeptidyl Peptidase 4 and Neprilysin Activity Enables Measurement of GLP-1 Secretion in Male Rats. [PDF]

J Endocr Soc
Galsgaard KD, Abba V, Kuhre RE, Holst JJ, Hartmann B.   +4 more
europepmc   +1 more source

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2113-2122, March 2026.
Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger, Christopher Filliter, Shahrzad Salmasi, Estefania Zapata‐Bravo, Robert W. Platt, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source